DexCom (NASDAQ:DXCM) Stock Price Up 7.7%

DexCom, Inc. (NASDAQ:DXCMGet Free Report)’s stock price traded up 7.7% during mid-day trading on Wednesday . The company traded as high as $131.80 and last traded at $131.19. 3,774,241 shares were traded during mid-day trading, an increase of 24% from the average session volume of 3,040,976 shares. The stock had previously closed at $121.78.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on DXCM. Morgan Stanley boosted their price objective on DexCom from $101.00 to $122.00 and gave the company an “equal weight” rating in a report on Monday, December 4th. Wells Fargo & Company upped their target price on DexCom from $110.00 to $136.00 and gave the stock an “overweight” rating in a report on Wednesday, December 13th. Raymond James upped their target price on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 23rd. Piper Sandler upped their price objective on DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 19th. Finally, StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Monday, February 12th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $134.64.

Read Our Latest Analysis on DexCom

DexCom Trading Down 0.4 %

The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. The firm has a fifty day moving average of $122.73 and a 200-day moving average of $108.70. The stock has a market capitalization of $51.37 billion, a price-to-earnings ratio of 101.71, a P/E/G ratio of 2.32 and a beta of 1.18.

DexCom (NASDAQ:DXCMGet Free Report) last posted its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm’s revenue for the quarter was up 26.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.34 EPS. As a group, equities analysts predict that DexCom, Inc. will post 1.74 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 392 shares of the stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $117.66, for a total transaction of $46,122.72. Following the transaction, the executive vice president now owns 76,008 shares of the company’s stock, valued at $8,943,101.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other DexCom news, EVP Sadie Stern sold 392 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $117.66, for a total value of $46,122.72. Following the sale, the executive vice president now owns 76,008 shares in the company, valued at $8,943,101.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven R. Altman sold 3,000 shares of DexCom stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $120.00, for a total value of $360,000.00. Following the sale, the director now directly owns 56,700 shares in the company, valued at approximately $6,804,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 55,262 shares of company stock valued at $6,794,399. Insiders own 0.41% of the company’s stock.

Institutional Investors Weigh In On DexCom

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bartlett & CO. Wealth Management LLC bought a new position in shares of DexCom in the fourth quarter valued at $27,000. DSM Capital Partners LLC purchased a new position in DexCom during the 4th quarter worth approximately $28,000. Valley National Advisers Inc. grew its position in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. Harbour Investments Inc. grew its position in DexCom by 55.6% during the 3rd quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock worth $31,000 after purchasing an additional 120 shares in the last quarter. Finally, Atlas Capital Advisors LLC purchased a new position in DexCom during the 2nd quarter worth approximately $33,000. Institutional investors own 93.88% of the company’s stock.

About DexCom

(Get Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Featured Articles

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.